Background {#s1}
==========

The role of inflammation in mood disorders has received increased attention ([@CIT0017]; [@CIT0051]; [@CIT0081]). Indeed, depression is prevalent in patients with inflammatory medical conditions, including cardiovascular diseases, rheumatoid arthritis, autoimmune disorders, obesity, or chronic hepatitis C (CHC; [@CIT0019]). Moreover, there is substantial evidence that cytokine therapies can induce depressive symptoms ([@CIT0047]; [@CIT0059]; [@CIT0034]). Not only is antiviral treatment for CHC associated with a high incidence of fatigue, insomnia, irritability and low mood, but full major depressive episodes (MDE) are also observed in around 25% of patients ([@CIT0053]).

Given that some patients are more likely to present depression during treatment with cytokines such as interferon alpha (IFN-alpha), research has focused on identifying social, clinical, and biological factors that may lead to neuropsychiatric side effects ([@CIT0067]). Previous studies and meta-analyses have shown several risk factors for IFN-induced depression, including clinical factors such as subthreshold depressive symptoms at baseline, a history of depression, and certain personality traits, as well as sociodemographic factors such as female gender and low educational level ([@CIT0057]; [@CIT0010]; [@CIT0053]; [@CIT0048]).

Although the exact neurobiological basis of cytokine-induced depression is not known, there is evidence that administration of an exogenous cytokine such as IFN-alpha modulates the function of cytokines such as interleukin-6 (IL-6) or interleukin-28 (IL-28; [@CIT0020]). In turn, this may result in both the treatment-induced antiviral response ([@CIT0036]) and antiviral-induced neuropsychiatric side effects ([@CIT0075]). Cytokine-induced alterations within the central nervous system (CNS) may depend on various mechanisms, including the passage of cytokines through leaky regions of the blood-brain barrier and activation of nervous pathways ([@CIT0002]). A high concentration of pro-inflammatory cytokines with activity in the CNS may modulate monoamine neurotransmission ([@CIT0059]), alter the glucocorticoid axis, and dysregulate apoptotic mechanisms ([@CIT0005]; [@CIT0003]; [@CIT0060]), which are factors related with the onset of clinical depression ([@CIT0002]). Specifically, immunological mechanisms may modulate the function of indoleamine 2,3-dioxygenase (IDO-1; [@CIT0037]), serotonin receptors (5HT1A; [@CIT0005]; [@CIT0042]), and catechol-O-methyl transferase (COMT; [@CIT0070]), and thereby alter serotonin and dopamine neurotransmission in certain brain regions involved with the pathogenesis of depression ([@CIT0023]). Equally, chronic activation of the immune system is known to cause increased plasma cortisol levels by desensitizing glucocorticoid receptors (GCR1 and GCR2; [@CIT0005]; [@CIT0066]) that may be modulated by proteins such as FK506-binding protein 5 (FKBP5), which is a co-chaperone of the glucocorticoid receptors ([@CIT0049]; [@CIT0031]). Lastly, high concentrations of cytokines in the CNS have been associated with dysregulation of brain apoptotic mechanisms, such as the brain-derived neurotrophic factor (BDNF), and with increases in the levels of several oxidative factors ([@CIT0025]).

In view of this evidence, the study of biological factors that may lead to IFN-induced neuropsychiatric symptoms is of potential interest, as it may help to improve the management of patients receiving antiviral treatment and illuminate the pathogenesis of depression. Thus, we aimed to investigate the association between IFN-induced depression and functional genetic variants in immunological factors (IL28), monoamine neurotransmission (IDO, 5HT1A, COMT), and the glucocorticoid axis (GCR1, GCR2, FKBP5), and neurotrophic factors (BDNF) in patients with CHC.

Methods {#s2}
=======

Selection of Patients {#s3}
---------------------

All consecutive Caucasian outpatients with CHC infection who were candidates for combination treatment with pegylated interferon-alpha (PegIFN alpha) and ribavirin (RBV) were recruited between 2005 and 2009 at the Liver Unit of a general teaching hospital (Parc de Salut Mar) in Barcelona. The exclusion criteria for the study were as follows: unable to understand the Catalan or Spanish languages, the presence of concomitant liver disease, decompensated cirrhosis or hepatocarcinoma, current drug or alcohol abuse, and any depressive episode within a 24-week period before starting treatment. The sample in this study partially overlapped with that described in a previous article ([@CIT0075]). The institutional review board at our hospitals (Parc de Salut Mar and Hospital Clínic) approved the study protocol and all participants provided written informed consent, including consent for genetic study.

Study Design {#s4}
------------

This study used a prospective cohort design. All patients were interviewed at baseline using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I; [@CIT0021]) to assess their current and past history of psychiatric disorders. At baseline, all patients also completed the Patient Health Questionnaire (PHQ; [@CIT0068]), the Hospital Anxiety and Depression Scale (HADS; [@CIT0082]), and the revised Temperament and Character Inventory (TCI-R; [@CIT0012]).

Patients started treatment with PegIFN alpha-2a (180 μg subcutaneously, per week) and RBV (800--1200mg orally, per day) for 24 or 48 weeks according to the Hepatitis C virus (HCV) genotype. After 4, 12, 24, and 48 weeks of treatment, patients again completed the HADS and the PHQ. If, at any point during the study, patients met the criteria for any depressive disorder according to the PHQ they were referred to a senior psychiatrist on the same day. After a full clinical assessment, the psychiatrists confirmed or rejected the diagnosis of depression, and initiated psychopharmacological treatment if needed.

Clinical Assessment {#s5}
-------------------

The validated Spanish version of the PHQ is designed to screen depressive and other psychiatric disorders in primary care and other medical settings ([@CIT0016]; [@CIT0053]). The items on the PHQ correspond to the symptom criteria for each disorder as outlined in the DSM-IV. The depression module (PHQ-9) has nine items with four response options: "Not at all," "Several days," "More than half the days," and "Nearly every day." We have also developed a categorical algorithm in which major depression is diagnosed if five or more of these criteria have been present at least "more than half the days" in the past 2 weeks, and if one of the symptoms is depressed mood or anhedonia; other depressive disorders are diagnosed if two, three, or four depressive symptoms have been present at least "more than half the days" in the past 2 weeks, and if one of the symptoms is depressed mood or anhedonia. The PHQ has good accuracy (95.2%) for detecting any depressive disorder in patients with CHC ([@CIT0053]). Moreover, the diagnosis of any depressive disorder through the PHQ has convergent validity with the scores of the depression subscale of the HADS ([@CIT0053]).

The HADS is a self-administered questionnaire with 14 items scored on a four-point Likert scale over depression and anxiety subscales (HADS-D and HADS-A). It is particularly useful for patients with comorbid medical conditions, as it excludes somatic or vegetative symptoms from the depression subscale. In this study, the validated Spanish version of the HADS was used ([@CIT0030]).

The TCI-R ([@CIT0012]) is a 240-item, five-point Likert scale, self-report questionnaire that measures seven personality dimensions. The biopsychosocial model by [@CIT0013] proposed that personality is formed by four temperament dimensions (harm avoidance, novelty seeking, reward dependence, and persistence) and three character dimensions (self-directedness, cooperativeness, and self-transcendence). Each dimension has three to five subscales measuring specific personality traits. The validated Spanish version of the TCI-R questionnaire ([@CIT0029]) was used in this study.

HCV RNA levels were measured by COBAS AMPLICOR HCV (Roche) at weeks 4, 12, and 24 and at week 48 in patients with genotype 1, and at week 24 after completion of antiviral treatment to evaluate sustained virological response.

Genetic Variant Selection {#s6}
-------------------------

We selected one variant in each of the following genes: interleukin-28 (IL28B; rs8099917); indoleamine 2,3-dioxygenase (*IDO-1*; rs3824259); 5-hydroxytryptamine (serotonin) receptor 1A (*HTR1A*; rs6295); COMT (rs4860); nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor; *NR3C1*; rs6196); nuclear receptor subfamily 3, group C, member 2 (NR3C2; rs5522); BDNF (rs6265); and FK506 binding protein 5 (*FKBP5*; rs1360780). To do so, we selected eight single nucleotide polymorphisms (SNPs) with a minor allele frequency higher than 10% in Caucasian populations that had previously been reported in the literature to be involved in psychiatric disorders or to be potentially functional in a public dbSNP database (<http://www.ncbi.nlm.nih.gov/SNP/>). Overall descriptions of each polymorphism are shown in [Table 1](#T1){ref-type="table"}.

###### 

Description of the Genetic Variants Included in the Study

  dbSNP ID\*   Gene    Chr.   Position\*\*   Alleles   Function/Location in gene         Genotyping Rate (%)   MAF    HWE
  ------------ ------- ------ -------------- --------- --------------------------------- --------------------- ------ ------
  rs6295       HTR1A   5      63294321       C/G       5' upstream                       99.1                  0.47   0.33
  rs4680       COMT    22     18331271       G/A       Coding non-synonymous Val158Met   100.0                 0.48   0.2
  rs6196       NR3C1   5      142641683      A/G       Coding synonymous                 99.7                  0.10   1.0
  rs5522       NR3C2   4      149576925      A/G       Coding non-synonymous Val180Ile   99.7                  0.09   0.75
  rs6265       BDNF    11     27636492       C/G       Coding non-synonymous Val66Met    100                   0.47   0.33
  rs3824259    IDO     8      39888750       T/G       5' upstream                       100                   0.48   0.33
  rs1360780    FKBP5   6      35715549       C/T       Intronic                          100                   0.29   0.29
  rs8099917    IL28B   19     44435005       T/G       5' upstream                       99.7                  0.21   0.62

\*Based in dbSNP 135 (<http://www.ncbi.nlm.nih.gov/projects/SNP>)

\*\*Mapped to Genome Build 36.3

BDNF = brain-derived neurotrophic factor; Chr = chromosome; COMT = Catechol-O-methyl transferase; FKBP5 = FK506 binding protein 5; HWE = Hardy-Weinberg equilibrium; HTR1A = 5-hydroxytryptamine (serotonin) receptor 1A; IDO = indoleamine 2,3-dioxygenase; IL28B = interleukin-28; MAF = minor allele frequency; NR3C1 = nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor); NR3C2 = nuclear receptor subfamily 3, group C, member 2.

SNP Genotyping {#s7}
--------------

SNPs were genotyped using a custom VeraCode GoldenGate Genotyping Assay (Illumina) according to the manufacturer's protocols (<http://www.illumina.com>). We used the Bead Studio software (Illumina) to process raw data, and genotypes were inferred via a genotyping cluster. For statistical analyses, we selected the SNPs with a minimum genotyping rate of 95% and in Hardy--Weinberg equilibrium (*p* \> 0.05; see [Table 1](#T1){ref-type="table"}).

Statistical Analysis {#s8}
--------------------

To study possible risk factors for the incidence of any depressive disorder, we used a survival analysis approach; a logistic model was inappropriate since the time under study was different between patients. Instead, the time from treatment start until the onset of the depression was chosen as the response variable of interest. Hence, right-censored data were given in the case of patients without depression during the study period, and the time to incidence was interval-censored between the last medical visit without depressive syndrome and the first after the onset, in all other cases. At a univariate level, the role of categorical variables was studied with the Fleming--Harrington test for interval-censored data based on a score vector distribution ([@CIT0026]), and the role of continuous variables by univariate Weibull regression models. All variables with a corresponding *p*-value below 0.25 were initially considered for the multivariate Weibull regression model, which is equivalent to the Cox proportional hazards model. The final model was obtained following the variable selection approach proposed by [@CIT0033]. Possible interactions were considered between all variables of the resulting model. The cumulative incidence of depression at weeks 24 and 48 was estimated using the Turnbull estimator for interval-censored data ([@CIT0073]). All statistical analyses were carried out with the statistical software package R (The R Foundation for Statistical Computing), version 3.2.1; in particular, we used the contributed packages survival (<https://cran.r-project.org/web/packages/survival/index.html>), FHtest (<https://cran.r-project.org/web/packages/FHtest/index.html>), and Icens (<http://www.bioconductor.org/packages/release/bioc/html/Icens.html>).

Results {#s9}
=======

Sample Characteristics {#s10}
----------------------

The clinical and sociodemographic characteristics of the 344 patients included in the study are displayed in [Table 2](#T2){ref-type="table"}.

###### 

Sample description and univariate analysis of variables

  --------------------------------------------------------------------------------------
                                     Whole sample\   Euthymic\     Depression\   
                                     n = 344         n = 209       n = 135       
  ---------------------------------- --------------- ------------- ------------- -------
  Gender                                                                         

   Female                            113 (32.8)      69 (33)       44 (32.6)     0.962

   Male                              231 (67.2)      140 (67)      91 (67.4)     

  Civil status                                                                   

   Engaged/married                   239 (69.5)      145 (69.4)    94 (69.6)     0.996

   Single                            62 (18)         37 (17.7)     25 (18.5)     

   Widow/divorced                    43 (12.5)       27 (12.9)     16 (11.9)     

  Education                                                                      

   Primary                           151 (43.9)      80 (38.3)     71 (52.6)     0.005

   Medium                            137 (39.8)      92 (44)       45 (33.3)     

   Superior                          56 (16.3)       37 (17.7)     19 (14.1)     

  Immigrant                                                                      

   No                                269 (78.2)      165 (78.9)    104 (77)      0.706

   Yes                               75 (21.8)       44 (21.1)     31 (23)       

  Job                                                                            

   Active                            257 (75.4)      161 (77.8)    96 (71.6)     0.169

   Unemployed/retired                84 (24.6)       46 (22.2)     38 (28.4)     

  Viral Genotype                                                                 

   1                                 194 (56.4)      122 (58.4)    72 (53.3)     0.410

   2                                 16 (4.7)        12 (5.7)      4 (3)         

   3                                 98 (28.5)       57 (27.3)     41 (30.4)     

   4                                 36 (10.5)       18 (8.6)      18 (13.3)     

  HIV infection                                                                  

   No                                275 (79.9)      179 (85.6)    96 (71.1)     0.004

   Yes                               69 (20.1)       30 (14.4)     39 (28.9)     

  Methadone treatment                                                            

   No                                330 (96.2)      199 (95.7)    131 (97)      0.396

   Yes                               13 (3.8)        9 (4.3)       4 (3)         

  Depression History                                                             

   No                                212 (62.7)      155 (76)      55 (42.5)     0.000

   Yes                               126 (37.3)      49 (24)       77 (57.5)     

  Anxiety History                                                                

   No                                248 (73.4)      163 (79.9)    85 (63.4)     0.001

   Yes                               90 (26.6)       41 (20.1)     49 (36.6)     

  Cocaine abuse history                                                          

   No                                252 (74.6)      158 (77.5)    94 (70.1)     0.206

   Yes                               86 (25.4)       46 (22.5)     40 (29.9)     

  Alcohol abuse history                                                          

   No                                273 (80.8)      171 (83.8)    102 (76.1)    0.060

   Yes                               65 (19.2)       33 (16.2)     32 (23.9)     

  Opioid abuse history                                                           

   No                                242 (71.6)      154 (75.5)    88 (65.7)     0.116

   Yes                               96 (28.4)       50 (24.5)     46 (34.3)     

  General psychiatric history                                                    

   No                                180 (52.8)      126 (61.2)    54 (40)       0.000

   Yes                               161 (47.2)      80 (38.8)     81 (60)       

  Family psychiatric history                                                     

   No                                219 (64.6)      134 (65)      85 (63.9)     0.797

   Yes                               120 (35.4)      72 (35)       48 (36.1)     

  Antidepressants at baseline                                                    

   No                                302 (87.8)      189 (90.4)    113 (83.7)    0.064

   Yes                               42 (12.2)       20 (9.6)      22 (16.3)     

  Quantitative variables             Mean (SD)       Mean (SD)     Mean (SD)     

  Age                                44 (10.4)       43.6 (10.4)   44.8 (10.3)   0.219

  HADS depression baseline           2.5 (2.8)       1.9 (2.2)     3.5 (3.2)     0.000

  Body mass index                    25.1 (4.5)      25.3 (4.2)    24.7 (4.9)    0.403

  Nº previous IFN treatments         1.2 (0.5)       1.2 (0.6)     1.2 (0.5)     0.730

  Quantitative variables             Mean (SD)       Mean (SD)     Mean (SD)     

  HADS anxiety baseline              4.5 (3.3)       3.9 (3.1)     5.5 (3.4)     0.000

  TCI-R Novelty Seeking              50.3 (9.9)      50.3 (9.7)    50.2 (10.3)   0.684

   Exploratory excitability          48.9 (10.4)     50.1 (10.2)   47 (10.4)     0.010

   Impulsiveness                     50.7 (10.2)     49.8 (9.8)    52.3 (10.7)   0.035

   Extravagance                      51.2 (10.2)     51.6 (10.2)   50.5 (10.1)   0.163

   Disorderliness                    49.9 (10.5)     49.2 (9.7)    51.2 (11.6)   0.151

  TCI-R Harm Avoidance               52.6 (10.4)     50.9 (10.3)   55.4 (9.9)    0.000

   Anticipatory worry                51 (9.9)        49.6 (10)     53.3 (9.3)    0.001

   Fear of uncertainty               50.9 (10.6)     50.4 (10.4)   51.7 (10.7)   0.213

   Shyness                           51.8 (10.1)     51 (9.7)      53 (10.6)     0.071

   Fatigability                      54.2 (11.4)     51.8 (10.7)   58 (11.4)     0.000

  TCI-R Reward Dependence            48.8 (9.5)      48.9 (8.8)    48.5 (10.7)   0.846

   Sentimentality                    47.9 (10.7)     47.7 (10)     48.2 (11.7)   0.570

   Openness to warm  communication   49 (13.7)       49 (12.6)     49 (15.2)     0.918

   Attachment                        49.3 (9.9)      49.2 (9.8)    49.4 (10.3)   0.886

   Dependence                        49.8 (10.6)     50.6 (10.4)   48.5 (10.8)   0.104

  TCI-R Persistence                  48.6 (10.9)     48.4 (10.5)   49 (11.5)     0.509

   Eagerness of effort               49.3 (11.1)     49.6 (10.8)   49 (11.5)     0.854

   Work hardened                     47.7 (10.3)     47.7 (10.4)   47.7 (10.3)   0.954

   Ambitious                         49.1 (12.1)     48.6 (11.4)   49.9 (13.1)   0.330

   Perfectionism                     49 (10.6)       48.6 (10.6)   49.8 (10.7)   0.250

  TCI-R Self-directedness            50.4 (10.5)     52.3 (10)     47.5 (10.7)   0.000

   Responsibility                    50.1 (11.3)     51.9 (10.3)   47.3 (12.3)   0.000

   Purposefulness                    49.3 (11.4)     50.6 (10.6)   47.2 (12.3)   0.007

   Resourcefulness                   50 (10.9)       51.1 (9.9)    48.3 (12.1)   0.019

   Self-acceptance                   50.3 (10.4)     51.5 (9.7)    48.4 (11.1)   0.014

   Enlightened second nature         51.2 (10.9)     52.4 (11)     49.4 (10.5)   0.027

  TCI-R Cooperativeness              49.5 (9.8)      50.8 (10)     47.5 (9.1)    0.010

   Social acceptance                 50 (9.8)        51.1 (9.7)    48.1 (9.7)    0.010

   Empathy                           49.6 (9.6)      50.1 (9.3)    48.8 (9.9)    0.303

   Helpfulness                       48.7 (9.7)      49.6 (9.5)    47.3 (9.9)    0.066

   Compassion                        49.2 (10.3)     50.1 (9.9)    47.8 (10.8)   0.080

   Poor-hearted consciousness        50.6 (11.2)     51.5 (11)     49.3 (11.4)   0.080

  TCI-R Self-Transcendence           51.3 (11)       50.7 (11)     52.2 (11.1)   0.218

   Self-forgetful                    50.6 (11.1)     50 (10.9)     51.5 (11.3)   0.231

   Transpersonal identification      50.8 (10.9)     50.6 (10.6)   51.1 (11.4)   0.511

   Spiritual acceptance              51.8 (11)       51.1 (10.8)   52.8 (11.4)   0.264
  --------------------------------------------------------------------------------------

HADS, Hospital Anxiety and Depression Scale; INF, interferon; SD, standard deviation; TCI-R, Temperament and Character Inventory, revised

Incidence of IFN-Induced Depression {#s11}
-----------------------------------

The cumulative incidence of depression was 0.35 at week 24 and 0.46 at week 48 (see [Figure 1](#F1){ref-type="fig"}). Some patients received treatment over 24 weeks and others over 48 weeks, depending on virus genotype and other medical criteria: the mean and median time under treatment were 37.3 and 47.8 weeks, respectively. The mean HADS-D score rate at the time of the first diagnosis of depression was 8.7 (standard deviation = 4.2). No suicidality was detected in the sample during the time of the study.

![Estimated cumulative incidence of depression during antiviral treatment.\
Shaded areas indicate that the estimation of the cumulative incidence is not defined in the corresponding intervals, but only known to increase monotonically.](ijnppy_pyv135_f0001){#F1}

Predictive Variables of IFN-Induced Depression {#s12}
----------------------------------------------

[Table 2](#T2){ref-type="table"} shows all the variables that were evaluated and the results of univariate analysis. All variables with a corresponding *p*-value below 0.25 were initially included in the multivariate analysis.

The multivariate model showed that older age (*p* = 0.018, HR associated to a 5-year increase = 1.21), a history of depression (*p* = 0.0001, HR = 2.38), and subthreshold depressive symptoms at baseline (*p* = 0.0050, HR = 1.13) increased the risk of IFN-alpha--induced depression. Concerning personality traits measured with the TCI-R, high scores on fatigability (*p* = 0.0037, HR associated to a 5-point increase = 1.17), impulsiveness (*p* = 0.0200, HR associated to a 5-point increase = 1.14), disorderliness (*p* = 0.0339, HR associated to a 5-point increase = 1.11), and low scores on extravagance (*p* = 0.0040, HR associated to a 5-point increase = 0.85) were risk factors for depression during antiviral treatment. A history of anxiety (*p* = 0.0955) and human immunodeficiency virus (HIV) infection (*p* = 0.0781) showed a trend toward an association with depression (see [Table 3](#T3){ref-type="table"}).

###### 

Multivariate Analysis

                                **Value**   **Standard error**   **CI (2.5- 97.5**)   ***p***   **HR**     
  ----------------------------- ----------- -------------------- -------------------- --------- ---------- ----------
  Age                           0.0652      0.0209               0.106                0.024     0.0018     1.21\*
  HIV infection                 -0.7146     0.4057               0.080                -1.510    0.0781     1.51
  History of mood disorder      -1.5142     0.3944               -2.287               -0.741    0.0001     2.38
  History of anxiety disorder   -0.6375     0.3824               -1.387               0.112     0.0955     1.44
  HADS score at baseline        -0.2195     0.0781               -0.373               -0.066    0.0050     1.13
  TCI HA: Fatigability          -0.0552     0.0190               -0.092               -0.018    0.0037     1.17\*\*
  TCI NS: Impulsiveness         -0.0468     0.0201               -0.086               -0.007    0.0200     1.14\*\*
  TCI NS: Extravagance          0.0551      0.0192               0.018                0.093     0.0040     0.85\*\*
  TCI NS: Disorderliness        0.0374      0.0176               -0.072               -0.003    0.0339     1.11\*\*
  5HT1A: G                      -2.3443     0.5966               -3.514               -1.175    \<0.0001   \-
  COMT: GG (Val/Val)            -2.0613     0.9225               -3.869               -0.253    0.0254     \-
  GCR1: G                       1.0495      0.5201               0.030                2.069     0.0436     0.55
  BDNF: GG (Val/Val)            -0.7460     0.3726               -1.476               -0.016    0.0453     1.53
  5HT1A \* COMT                 3.7231      1.0943               1.578                5.868     0.0007     
  \- Val/Val: G vs. CC                                                                                     0.45
  \- Met: G vs. CC                                                                                         3.83
  \- CC:Val/Val vs. Met                                                                                    3.25
  \- G:Val/Val vs. Met                                                                                     0.39

Variables included in the analysis and with *p* \< 0.1.

\*Hazard ratio associated to a 5 years' increase

\*\*Hazard ratios associated to a 5 points' increase

BDNF, brain-derived neurotrophic factor; CI, confidence interval; COMT, catechol-O-methyl transferase; HA, harm avoidance; HADS, Hospital Anxiety and Depression Scale; HR, hazard ratio; NS, novelty seeking; TCI, Temperament and Character Inventory

With regard to genetic polymorphisms, the following were risk factors for depression during antiviral treatment: being homozygous for the A allele of the GCR1 polymorphism (*p* = 0.029, HR = 1.88) and the genotype GG of the BDNF polymorphism (*p* = 0.0453 HR = 1.53; see [Table 3](#T3){ref-type="table"}).

Interaction Between Variables {#s13}
-----------------------------

In addition, we found an interaction between the *HTR1A* and COMT genes: patients carrying the *HTR1A* G allele had a higher risk of depression than those with the CC genotype if they also carried the A allele (Met/Met or Val/Met) of the COMT polymorphism (HR = 3.83). The G allele was not a risk factor in patients with the GG genotype (Met/Met) of COMT (HR = 0.45). Among patients with the *HTR1A* CC genotype, those patients carrying the COMT GG genotype were at a higher risk of depression during antiviral treatment than patients carrying the A allele (HR = 3.25), whereas the GG allele was not a risk factor in patients with the HTR1AC G genotype (HR = 0.39; see [Table 3](#T3){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). No other interactions were found between any other variables studied.

![Estimated cumulative incidence of depression according to genotypes of *HTR1A* and COMT genes. Shaded areas indicate that the estimation of the cumulative incidence is not defined in the corresponding intervals, but only known to increase monotonically.](ijnppy_pyv135_f0002){#F2}

Discussion {#s14}
==========

We evaluated the impact on mood of initiating IFN-alpha and ribavirin treatment in a cohort of 344 euthymic patients with CHC. We found a higher incidence of depression in elderly patients, those with a history of depression, and those with depressive symptoms at baseline, as well as with certain personality traits. In addition, significant associations were found with functional variants of genes, such as *GCR1* and BDNF, and with combinations of *HTR1A* and COMT genes. Notably, the incidence of depression was higher in patients carrying both the Met substitution in COMT and the G allele in *HTR1A* and in those carrying both the Val/Val substitution in COMT and the CC genotype *HTR1A*. To our knowledge, this is the first report of an association between a *GCR1* gene polymorphism and IFN-alpha treatment-related depression.

The cumulative incidence of depression during antiviral treatment was similar to previous reports ([@CIT0062]; [@CIT0010]). Some authors, however, have observed a lower incidence of IFN-induced depression ([@CIT0038]; [@CIT0061]), probably due to the exclusion of patients with a history of depression or concomitant viral infections such as HIV.

According to our results, a previous history of depression and the presence of subthreshold depressive symptoms at baseline were both predictors of IFN-induced depression. A history of anxiety and HIV infection only showed a trend toward association. These have consistently been reported as risk factors in previous clinical studies and meta-analyses ([@CIT0058]; [@CIT0010]; [@CIT0053]).

Our finding of an association between certain personality traits and IFN-induced depression was also interesting. Previous studies have reported that high harm-avoidance, low self-direction, and high neuroticism may be related to IFN-induced depression ([@CIT0045]; [@CIT0010]). In our study, all traits associated with depression (fatigability, impulsiveness, disorderliness, extravagance) were from two temperamental dimensions of the TCI-R: harm avoidance and novelty seeking. Temperamental dimensions assess differences in automatic emotional responses to stimuli, define personality style, and are influenced by different neurotransmitter systems. Harm avoidance refers to a tendency to shyness and anxiety, and has been associated with serotonergic function ([@CIT0072]), while novelty seeking reflects reward system activity and has been related to mesolimbic and mesocortical dopaminergic projections ([@CIT0004]; [@CIT0071]). However, despite these overall trends, we found no interactions between these variables and the functional polymorphisms examined.

The current study also found an association between the *HTR1A* polymorphism and IFN-alpha induced depression. The results are in agreement with those reported by [@CIT0038], where patients carrying the G allele of the *HTR1A* gene were at a higher risk of depression during antiviral treatment. Moreover, the same polymorphism has previously been associated with panic disorder, neuroticism, depression, and reduced response to antidepressant treatment ([@CIT0042]). We found that the G allele in *HTR1A* only predicted depression in patients also carrying the A allele (Met substitution) in the COMT gene (n = 141). Interestingly, a small group of patients (n = 33) carrying the GG genotype in the COMT polymorphism (Val/Val substitution) together with the CC genotype in the *HTR1A* polymorphism also showed a higher incidence of depression. Importantly, both patient subgroups had more than a three-fold higher risk of depression during interferon treatment than those without this combination. The risk for these patients was even higher than in patients with a history of depression (HR 2.35), which is the most replicated and strongest risk factor for developing IFN-induced depression ([@CIT0010]; [@CIT0022]; [@CIT0053]).

Overall, these results suggest that both serotonin and dopamine pathways are important in the development of depression during antiviral treatment for CHC. On the one hand, the G allele of *HTR1A* may alter transcription in serotonergic and non-serotonergic neurons and confers a higher susceptibility to depression and suicide ([@CIT0043]). Specifically, the G allele up-regulates 5-HT~1A~ autoreceptor expression, which reduces serotonergic function in the forebrain and may also alter dopaminergic neurotransmission ([@CIT0078]; [@CIT0001]). Furthermore, 5-HT~1A~ receptors modulate the activity of dopaminergic neurons in the ventral tegmental area and regulate mesocortical dopamine release ([@CIT0015]). [@CIT0008] also reported alterations in dopaminergic neurons after IFN-alpha administration that might be associated with anhedonia, fatigue, and other behavioral changes. On the other hand, dopamine plays a critical role in prefrontal cortex function in an inverted U-shaped manner, with both too much and too little dopamine being associated with a higher risk of depression ([@CIT0050]; [@CIT0032]). Such a phenomenon might explain the interaction between the COMT and *HTR1A* polymorphisms. The A allele (Met/Met or Val/Met) in the COMT polymorphism is related to lower activity of the enzyme, and therefore probably to a higher concentration of dopamine in the prefrontal cortex ([@CIT0014]). Moreover, the G allele of the *HTR1A* polymorphism may be associated with an up-regulation of 5HT~1A~ receptor expression in the prefrontal cortex and a further release of dopamine. Therefore, patients carrying both alleles (COMT A and *HTR1A* G) may develop abnormally high concentrations of dopamine in the prefrontal cortex, leading to a higher risk of IFN-induced depression. Alternatively, patients who simultaneously carry the GG genotype (Val/Val) in the COMT gene and the CC genotype in the *HTR1A* polymorphism may have abnormally low concentrations of dopamine that also result in a higher risk for depression. This theory is biologically plausible because patients with the other genotypes would have intermediate levels of dopamine and would therefore be at a lower risk of developing depression.

A novel association between GCR1 and antiviral-induced depression is worthy of note. Genetic variants of the *GCR1* gene have been associated with changes in corticosteroid resistance ([@CIT0039]), major depressive disorders ([@CIT0069]; [@CIT0024]), and a predominance of depression in the course of bipolar disorder ([@CIT0069]). This observation may be related to the cytokine-induced activation of the hypothalamic-pituitary-adrenal axis, a physiological condition often related to depression ([@CIT0079]; [@CIT0044]). Specifically, chronic administration of IFN-alpha is associated with a desensitization of the hypothalamic-pituitary-adrenal axis, leading to a reduced negative feedback regulation and increased plasma cortisol levels ([@CIT0007]; [@CIT0005]; [@CIT0066]). Hence, a reduction in glucocorticoid receptor mRNA levels has been reported in patients with major depression ([@CIT0080]; [@CIT0055]). Interestingly, IFN-alpha markedly down-regulated HTR1A and GCR1 receptors in cell lines *in vitro*, an effect that was attenuated by the administration of antidepressants ([@CIT0005]). In this line, clinical studies showed that prophylactic administration of antidepressants reduces the incidence of IFN-induced depression ([@CIT0076]).

Lastly, we found an association between the BDNF polymorphism and depression during antiviral treatment. It is possible that activation of cytokines and inflammatory mediators in the brain could produce excitotoxicity and alterations in neurotrophic factors. Indeed, cytokines may stimulate the release of glutamate from glial cells and alter glutamate reuptake through glutamate transporters ([@CIT0052]). The subsequent excessive activation of N-methyl-D-aspartate receptors by glutamate could then cause oxidative stress by producing reactive species of oxygen and nitrogen, thereby altering the expression of trophic factors such as BDNF ([@CIT0052]; [@CIT0006]). According to our results, the Val genotype of BDNF was associated with IFN-induced depression. In addition, this genotype was also associated with higher neurotic scores and with anxiety- and depression-related personality traits, suggesting a relationship with depression ([@CIT0065]; [@CIT0041]). Conversely, some studies have reported an association between the Met genotype and increased serum concentrations of BDNF ([@CIT0040]) and with a risk factor for anxiety disorders, major depression ([@CIT0035]), and even INF-induced depression ([@CIT0046]). [@CIT0027] reported that the Met allele increases the risk of eating disorders and schizophrenia, while reducing the risk of substance-related disorders. [@CIT0011] showed that increased BDNF concentrations in the hippocampus mimic the effects of antidepressants on behavior, but that injection of BDNF into the mesolimbic dopamine pathway produces an opposing response. As described in previous studies and meta-analyses, the association between the BDNF Val66Met polymorphism and different psychiatric conditions is complex ([@CIT0028]; [@CIT0077]). It is likely that neurotrophic factors themselves do not control mood, but that they may be crucial to the modulation of neural networks involved in the pathogenesis of depression, including serotonergic or dopaminergic pathways ([@CIT0011]; [@CIT0028]).

This study has some strengths and limitations. We controlled for potential confounding variables at baseline, such as antidepressant use, a history of depression, and other relevant sociodemographic variables, and did not find an interaction between these variables and the polymorphisms examined. Although we did not control for antidepressant therapy being initiated during antiviral treatment, we doubt that this would influence our conclusions because therapy was only initiated after the clinical diagnosis of depression.

Sample size and the all-Caucasian population are also limitations. To our knowledge, only two genetic studies evaluating patients with CHC under antiviral treatment have had larger samples; however, neither study used a standardized clinician-administered assessment to establish the diagnosis of depression ([@CIT0056]; Smith et al., 2011), which we believe is a strength of our study. Nevertheless, it should be noted that antiviral treatment can induce two overlapping syndromes: a specific psychiatric syndrome of mood alterations, cognitive complaints, and anxiety, and a non-specific syndrome of neurovegetative symptoms ([@CIT0057]). In this study, we only assessed patients using the HADS scale, which specifically excludes neurovegetative symptoms and avoids overlapping with other depression symptoms; this may be somewhat counterbalanced by the fact that the mean HADS-D score was 8.7 at the onset of depression, suggesting the presence of a depressive episode with high sensitivity and specificity ([@CIT0054]). Another limitation of the study is that specific neuropsychiatric symptoms of depression were not evaluated, which may be important. For example, insomnia has been associated with increased cytokine concentrations and with a polymorphism in the serotonin transporter gene ([@CIT0046]).

Lastly, we did not find an association between the *IDO*, *IL28*, *FKBP5*, and *GCR2* genetic variants. However, these results should be interpreted with care due to the small number of polymorphisms evaluated. For example, a previous study showed an association between another *IDO* gene variant (rs9657182) and IFN-induced depression, suggesting that IDO may have an important role in cytokine-induced behavioral changes (Smith et al., 2011).

In conclusion, this study supports the notion that IFN-induced depression is a complex pathophysiological process in which specific factors interact with physiological changes that are associated with depressive symptoms. Consistent with previous reports, the serotonin pathway was important in the development of depression. However, factors such as the integrity of dopamine neurotransmission, vulnerability to glucocorticoid resistance, and neurotrophin function may also be crucial.

Moreover, the results of the study should help to optimize the managment of patients with CHC, detecting those at high risk to present IFN-induced depression. In fact, recent guidelines recommend multidisciplinary monitoring for psychiatric symptoms during antiviral treatment for CHC in all cases ([@CIT0064]; [@CIT0009]). However, those in high risk to present depression may well benefit from certain interventions such as prophilactical treatment with antidepressants ([@CIT0076]). Although interferon-free regimens with direct-acting antivirals are recent options, currently interferon-alpha is still widely used in CHC in most countries ([@CIT0018]).
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